Alexander Porter, MD, Director of Medical Affairs, BioMarin Pharmaceutical Inc., Caren Arstein, Vice President of Corporate Communications, Genzyme Corp. David Pendergast, PhD, Executive Vice President and General Manager of Shire, and Steve Holland, President of MPS Society Ring The NASDAQ Stock Market Closing Bell.

Friday, February 24, 2006
at NASDAQ's MarketSite
in New York City.

Shire plc

Dr. David D. Pendergast, executive vice president and general manager of Shire plc, presides over the closing bell. Dr. Pendergast oversees operations at Shire Human Genetic Therapies, the Shire specialty unit focused specifically on genetic diseases. M&A activity for Shire during the last several years has resulted in six completed acquisitions, and they have plans to launch five products in 2006, including, ELAPRASE, which if approved by regulators, will be the first human enzyme replacement therapy for the treatment of Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II), a rare genetic disorder.

Click for larger pictures of the NASDAQ MarketSite. Additional Photographs for 2/24/2006 Download Hi-Res Quality Photo of this NASDAQ Market Close - Pictured: Steve Holland, President of MPS Society rings the Closing Bell. These photos are Copyright 2006, The Nasdaq Stock Market Inc. and available for re-publication by the news media only. Any commercial use is strictly prohibited without the prior written consent of The Nasdaq Stock Market Inc. © Copyright 2006, The NASDAQ Stock Market, Inc. Reprinted with the permission of The Nasdaq Stock Market, Inc.